BRIEF-EMA Recommends Converting Marketing Authorisation Of Jcovden Shot To A Standard One

European Medicines Agency: * EMA: RECOMMENDED CONVERTING CONDITIONAL MARKETING AUTHORISATION OF COVID-19 VACCINE JCOVDEN TO A STANDARD MARKETING AUTHORISATION

* EMA: CHMP ADOPTED POSITIVE OPINION FOR IMJUDO TO BE USED IN COMBINATION WITH IMFINZI FOR TREATMENT OF ADULTS WITH HEPATOCELLULAR CARCINOMA * EMA: RECOMMENDED TO EXTEND USE OF ORIGINAL SPIKEVAX VACCINE, SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 AS BOOSTER DOSE IN CHILDREN AGED 6 TO 11 YEARS

* EMA SAYS CHMP RECOMMENDED GRANTING A CONDITIONAL MARKETING AUTHORISATION FOR THE ADVANCED THERAPY MEDICINAL PRODUCT (ATMP) HEMGENIX * EMA: CHMP ADOPTED POSITIVE OPINION FOR TREMELIMUMAB ASTRAZENECA

* EMA: CHMP ADOPTED POSITIVE OPINION FOR POMBILITI FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE II Further company coverage: